Clinical Trials on Stage II Mycosis Fungoides/Sezary Syndrome

Total 187 results

Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Mycosis Fungoides | Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Recurrent Mycosis Fungoides... and other conditions

United States
Northwestern University
Amgen

Terminated

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Recurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Withdrawn

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Recurrent Mycosis Fungoides and Sezary Syndrome | Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IIB Mycosis Fungoides and Sezary Syndrome | Stage IIIA Mycosis Fungoides and Sezary Syndrome | Stage IIIB Mycosis Fungoides and Sezary Syndrome | Stage IVA Mycosis Fungoides and Sezary Syndrome | Stage...
Kevin Cooper MD
National Cancer Institute (NCI)

Completed

Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IA Mycosis Fungoides/Sezary Syndrome | Stage IB Mycosis Fungoides/Sezary Syndrome | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IIA Mycosis...

United States
Northwestern University
National Cancer Institute (NCI); Celgene

Active, not recruiting

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome | Sézary | Advanced Mycosis Fungoides

United States
National Cancer Institute (NCI)

Completed

506U78 in Treating Patients With Lymphoma

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Small Intestine Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis... and other conditions

United States
Kyowa Kirin Pharmaceutical Development Ltd

Recruiting

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) (PROSPER)

Mycosis Fungoides and Sézary Syndrome

Spain, United Kingdom, Netherlands, United States, Italy
National Cancer Institute (NCI)

Completed

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7

United States
European Organisation for Research and Treatment...
Hoffmann-La Roche

Terminated

PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) (PARCT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Spain, Switzerland
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; MorphoSys AG; Swim Across America; Daniel...

Recruiting

Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome

United States
Virginia Commonwealth University
Seagen Inc.

Completed

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Mycosis Fungoides | Sézary Syndrome

United States
European Organisation for Research and Treatment...
Mallinckrodt

Withdrawn

Study of Photopheresis in the Treatment of Erythrodermic MF and SS (PROMPT)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

Switzerland
Innate Pharma

Active, not recruiting

IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK)

Lymphoma, T-Cell | Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides/Sezary Syndrome

United States, Spain, France, Italy, Belgium, Austria, Germany, Poland
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Stage I Mycosis Fungoides | Stage II Mycosis Fungoides | Stage III Mycosis Fungoides

United States
Elorac, Inc.

Terminated

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sézary Syndrome

United States
University College, London
Merck Sharp & Dohme LLC

Active, not recruiting

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT)

Cutaneous T Cell Lymphoma | Mycosis Fungoides/Sezary Syndrome

United Kingdom
Neumedicines Inc.
National Cancer Institute (NCI)

Unknown

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Mycosis Fungoides | Sézary Syndrome | Cutaneous T Cell Lymphoma (CTCL)

United States
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (FIL_MOGA)

Cutaneous T Cell Lymphoma | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Cutaneous T-Cell Lymphoma/Sezary Syndrome

Italy
National Cancer Institute (NCI)

Terminated

506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome

United States
Icahn School of Medicine at Mount Sinai
Pfizer

Recruiting

Ritlecitinib in CTCL

Mycosis Fungoides | Sezary Syndrome | CTCL

United States
Northwestern University
National Cancer Institute (NCI); Eli Lilly and Company

Terminated

Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Lymphoma

United States
Stanford University

Recruiting

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome

United States
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
Emergent Product Development Seattle LLC

Terminated

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome

United States, Spain, France, Germany, Italy
Latin American Cooperative Onco-Haematology Group...

Unknown

Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

Mycosis Fungoides | Sezary Syndrome

Peru
City of Hope Medical Center

Withdrawn

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Sezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

Lymphoma

United States
Lund University Hospital

Recruiting

Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. (BIO-MUSE)

Mycosis Fungoides | Sezary Syndrome

Sweden
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Mycosis Fungoides | Sezary Syndrome | Lymphomatoid Papulosis

United States
Northwestern University
Genzyme, a Sanofi Company; Millennium Pharmaceuticals, Inc.

Completed

Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome

Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Lymphoma

United States
Eisai Inc.

Completed

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Germany, Canada, Australia, United Kingdom, Austria, Russian Federation, United States, Poland, Switzerland
Stanford University

Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Non-Hodgkin's Lymphoma | Mycosis Fungoides

United States, China, Argentina, Australia, Brazil, Japan, United Kingdom
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Recruiting

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Cutaneous T Cell Lymphoma | Fungoides Mycosis Sezary Syndrome

United States
Northwestern University
Seagen Inc.

Terminated

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell... and other conditions

United States
4SC AG

Completed

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat

Mycosis Fungoides | Sezary Syndrome | Cutaneous T Cell Lymphoma

United Kingdom
University of Texas Southwestern Medical Center

Withdrawn

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Cutaneous T-Cell Lymphomas

United States
Kyowa Kirin China Pharmaceutical Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Cutaneous T-Cell Lymphoma

China
Eisai Inc.

Completed

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Germany, Canada, United Kingdom, Austria, Russian Federation, United States, Australia, Poland, Switzerland, Netherlands
University of Washington
National Cancer Institute (NCI)

Completed

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States

Clinical Trials on Stage II Mycosis Fungoides/Sezary Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations